Transcriptomics

Dataset Information

0

Computational Repurposing of Bumetanide for Preventing or Treating Alzheimer’s Disease [AT01_J20_apoEKI_Bumex_snRNA-seq]


ABSTRACT: The evident genetic, pathological, and clinical heterogeneity of Alzheimer’s disease (AD) poses challenges for traditional drug development. We conducted a computational drug repurposing screen for drugs to treat apolipoprotein (apo) E4-related AD. We first established apoE-genotype-dependent transcriptomic signatures of AD by analyzing publicly-available human brain database. We then queried these signatures against the Connectivity Map database containing transcriptomic perturbations of >1300 drugs to identify those that best reverse apoE-genotype-specific AD signatures. Bumetanide was identified as a top drug for apoE4 AD. Bumetanide treatment of apoE4 mice without or with Ab accumulation rescued electrophysiological, pathological, or cognitive deficits. Single-nucleus RNA-sequencing revealed transcriptomic reversal of AD signatures in specific cell types in these mice, a finding confirmed in apoE4-iPSC-derived neurons. In humans, bumetanide exposure was associated with a significantly lower AD prevalence in individuals over the age of 65 in two EHR databases, suggesting effectiveness of bumetanide in preventing AD.

ORGANISM(S): Mus musculus

PROVIDER: GSE182764 | GEO | 2021/10/03

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-10-03 | GSE182762 | GEO
2021-10-03 | GSE182761 | GEO
2023-07-20 | PXD036416 | Pride
2024-07-08 | GSE271384 | GEO
2024-07-08 | GSE271385 | GEO
2021-03-23 | PXD023340 | Pride
2024-10-04 | GSE252454 | GEO
2012-12-15 | E-GEOD-42930 | biostudies-arrayexpress
2022-06-15 | GSE125501 | GEO
2023-08-31 | GSE206314 | GEO